PL3118311T3 - Antysensowny kwas nukleinowy - Google Patents

Antysensowny kwas nukleinowy

Info

Publication number: PL3118311T3
Authority: PL; Poland
Prior art keywords: antisensive; nucleic acid; nucleic; acid; antisensive nucleic
Prior art date: 2014-03-12

Application number

PL15761392T

Other languages

English (en)

Inventor

Tatsushi Wakayama

Haruna SEO

Youhei Satou

Shin'ichi Takeda

Tetsuya Nagata

Original Assignee

Nippon Shinyaku Co., Ltd.

National Center Of Neurology And Psychiatry

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-12

Filing date

2015-03-11

Publication date

2019-09-30

2015-03-11 Application filed by Nippon Shinyaku Co., Ltd., National Center Of Neurology And Psychiatry filed Critical Nippon Shinyaku Co., Ltd.

2019-09-30 Publication of PL3118311T3 publication Critical patent/PL3118311T3/pl

Links

150000007523 nucleic acids Chemical class 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL15761392T 2014-03-12 2015-03-11 Antysensowny kwas nukleinowy PL3118311T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2014048897		2014-03-12
EP15761392.8A EP3118311B1 (en)	2014-03-12	2015-03-11	Antisense nucleic acid
PCT/JP2015/057180 WO2015137409A1 (ja)	2014-03-12	2015-03-11	アンチセンス核酸

Publications (1)

Publication Number	Publication Date
PL3118311T3 true PL3118311T3 (pl)	2019-09-30

Family

ID=54071850

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15761392T PL3118311T3 (pl)	2014-03-12	2015-03-11	Antysensowny kwas nukleinowy

Country Status (31)

Country	Link
US (5)	US9988629B2 (pl)
EP (2)	EP3118311B1 (pl)
JP (1)	JP6606488B2 (pl)
KR (1)	KR102335801B1 (pl)
CN (2)	CN110951732A (pl)
AU (2)	AU2015227733B2 (pl)
BR (1)	BR112016020618B1 (pl)
CA (1)	CA2939948A1 (pl)
CY (1)	CY1121322T1 (pl)
DK (1)	DK3118311T3 (pl)
ES (1)	ES2710802T3 (pl)
HR (1)	HRP20190235T1 (pl)
HU (1)	HUE042283T2 (pl)
IL (1)	IL247663B (pl)
LT (1)	LT3118311T (pl)
MX (1)	MX2016011538A (pl)
MY (1)	MY193708A (pl)
NZ (1)	NZ724836A (pl)
PH (1)	PH12016501761B1 (pl)
PL (1)	PL3118311T3 (pl)
PT (1)	PT3118311T (pl)
RS (1)	RS58573B1 (pl)
RU (2)	RU2730681C2 (pl)
SG (1)	SG11201607095RA (pl)
SI (1)	SI3118311T1 (pl)
SM (1)	SMT201900169T1 (pl)
TR (1)	TR201901939T4 (pl)
TW (2)	TWI672314B (pl)
UA (1)	UA120849C2 (pl)
WO (1)	WO2015137409A1 (pl)
ZA (1)	ZA201605864B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112016020618B1 (pt) *	2014-03-12	2023-04-04	Nippon Shinyaku Co., Ltd.	Oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
PT3159409T (pt)	2014-06-17	2020-01-21	Nippon Shinyaku Co Ltd	Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne
HUE050061T2 (hu)	2015-09-15	2020-12-28	Nippon Shinyaku Co Ltd	Antiszensz nukleinsav
MA46427A (fr)	2015-10-09	2018-08-15	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
KR102775461B1 (ko)	2016-04-01	2025-02-28	어비디티 바이오사이언시스 인크.	핵산-폴리펩타이드 조성물 및 이의 용도
KR20190024977A (ko)	2016-06-30	2019-03-08	사렙타 쎄러퓨틱스 인코퍼레이티드	근육 이상증에 대한 엑손 스킵핑 올리고머
US20190330626A1 (en) *	2016-07-15	2019-10-31	Ionis Pharmaceuticals, Inc.	Compounds and methods for use in dystrophin transcript
EP3516061A1 (en) *	2016-09-23	2019-07-31	Synthena AG	Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
ES3051834T3 (en)	2016-12-19	2025-12-30	Sarepta Therapeutics Inc	Exon skipping oligomer conjugates for muscular dystrophy
NZ755416A (en)	2016-12-19	2023-05-26	Sarepta Therapeutics Inc	Exon skipping oligomer conjugates for muscular dystrophy
PT4122497T (pt)	2016-12-19	2024-06-12	Sarepta Therapeutics Inc	Conjugados oligoméricos de salto de exão para a distrofia muscular
KR20240172236A (ko) *	2017-01-06	2024-12-09	어비디티 바이오사이언시스 인크.	핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
GB201711809D0 (en)	2017-07-21	2017-09-06	Governors Of The Univ Of Alberta	Antisense oligonucleotide
EA201991450A1 (ru)	2017-09-22	2019-12-30	Сарепта Терапьютикс, Инк.	Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
TWI812647B (zh)	2017-09-25	2023-08-21	美商薩羅塔治療公司	經由速流合成以製備磷醯二胺嗎啉代寡聚物之製程
JP2020536060A (ja)	2017-09-28	2020-12-10	サレプタセラピューティクス，インコーポレイテッド	筋ジストロフィーを処置するための併用療法
JP2021521140A (ja)	2018-04-12	2021-08-26	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en)	2018-05-11	2019-11-14	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
US10765760B2 (en)	2018-05-29	2020-09-08	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
WO2019240223A1 (ja) *	2018-06-13	2019-12-19	公益財団法人川崎市産業振興財団	数平均分子量が３ｋＤａ～１０ｋＤａであるＰＥＧブロックとカチオン性ポリマーとのブロックコポリマーと、アンチセンスオリゴヌクレオチドとを含む、ポリイオンコンプレックスミセル
US11168141B2 (en)	2018-08-02	2021-11-09	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en)	2018-08-02	2024-06-25	Dyne Therapeutics, Inc.	Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3830259A4 (en)	2018-08-02	2022-05-04	Dyne Therapeutics, Inc.	MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
WO2020028832A1 (en)	2018-08-02	2020-02-06	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12331293B2 (en) *	2018-11-02	2025-06-17	Biomarin Technologies B.V.	Bispecific antisense oligonucleotides for dystrophin exon skipping
AU2019392928A1 (en) *	2018-12-06	2021-06-17	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
CN113660938A (zh) *	2019-01-30	2021-11-16	国立研究开发法人国立精神·神经医疗研究中心	核酸递送复合物
WO2020219820A1 (en)	2019-04-25	2020-10-29	Avidity Biosciences, Inc.	Nucleic acid compositions and methods of multi-exon skipping
EP4079329A4 (en) *	2019-12-19	2024-04-17	Nippon Shinyaku Co., Ltd.	ANTISENSE NUCLEIC ACID ENABLING EXON SKIPPING
PE20230237A1 (es) *	2020-02-28	2023-02-07	Nippon Shinyaku Co Ltd	Acidos nucleicos antisentido que inducen la omision del exon 51
US11771776B2 (en)	2021-07-09	2023-10-03	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en)	2021-07-09	2024-04-30	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en)	2021-07-09	2023-05-02	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2022232478A1 (en)	2021-04-30	2022-11-03	Sarepta Therapeutics, Inc.	Treatment methods for muscular dystrophy
WO2023283623A1 (en)	2021-07-09	2023-01-12	Dyne Therapeutics, Inc.	Muscle targeting complexes and formulations for treating dystrophinopathies
KR20240129006A (ko)	2021-12-27	2024-08-27	니뽄 신야쿠 가부시키가이샤	올리고 핵산 화합물의 제조 방법
JPWO2023171804A1 (pl)	2022-03-10	2023-09-14
EP4493693A1 (en)	2022-03-17	2025-01-22	Sarepta Therapeutics, Inc.	Phosphorodiamidate morpholino oligomer conjugates
US12071621B2 (en)	2022-04-05	2024-08-27	Avidity Biosciences, Inc.	Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
ATE312834T1 (de)	1989-12-20	2005-12-15	Avi Biopharma Inc	Ungeladene, auf morpholin basierende polymere mit chiralen, phosphor enthaltenden brücken zwischen den untereinheiten
JP2924179B2 (ja)	1993-02-19	1999-07-26	日本新薬株式会社	グリセロール誘導体，デバイス及び医薬組成物
IL115849A0 (en)	1994-11-03	1996-01-31	Merz & Co Gmbh & Co	Tangential filtration preparation of liposomal drugs and liposome product thereof
EP1191097A1 (en) *	2000-09-21	2002-03-27	Leids Universitair Medisch Centrum	Induction of exon skipping in eukaryotic cells
EP2530155B1 (en) *	2002-11-25	2016-03-16	Masafumi Matsuo	ENA nucleic acid drugs modifying splicing in mRNA precursor
ES2627917T3 (es) *	2004-06-28	2017-08-01	The University Of Western Australia	Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
EP1811024A1 (en)	2004-10-05	2007-07-25	Nippon Shinyaku Co., Ltd.	Oligo double-stranded rna and medicinal composition
US20090312532A1 (en) *	2005-04-22	2009-12-17	Van Deutekom Judith Christina	Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secodary rna structure
WO2006129594A1 (ja)	2005-05-30	2006-12-07	Nippon Shinyaku Co., Ltd.	核酸含有複合体製剤の製造方法
US8067571B2 (en) *	2005-07-13	2011-11-29	Avi Biopharma, Inc.	Antibacterial antisense oligonucleotide and method
RU2418068C2 (ru) *	2005-08-17	2011-05-10	Сирна Терапьютикс, Инк.	Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
EP1963538A2 (en) *	2005-11-30	2008-09-03	Guild Associates, Inc.	Differentially fluorescent yeast biosensors for the detection and biodegradation of chemical agents
EP2119738B1 (en)	2007-02-05	2014-04-16	Nippon Shinyaku Co., Ltd.	Polyethylene glycol derivative
NZ584793A (en)	2007-10-26	2012-05-25	Academisch Ziekenhuis Leiden	Means and methods for counteracting muscle disorders
MX2010004955A (es)	2007-11-15	2010-06-30	Avi Biopharma Inc	Metodo de sintesis de oligomeros de morfolina.
US8084601B2 (en)	2008-09-11	2011-12-27	Royal Holloway And Bedford New College Royal Holloway, University Of London	Oligomers
EP3133160B1 (en)	2008-10-24	2018-12-12	Sarepta Therapeutics, Inc.	Exon skipping compositions for dmd
SI2607484T1 (sl) *	2008-10-27	2016-11-30	Biomarin Technologies B.V.	Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
US20110269665A1 (en)	2009-06-26	2011-11-03	Avi Biopharma, Inc.	Compound and method for treating myotonic dystrophy
HUE040445T2 (hu) *	2009-11-12	2019-03-28	Univ Western Australia	Antiszensz molekulák és eljárások betegségek kezelésére
KR101981705B1 (ko)	2010-05-28	2019-05-24	사렙타 쎄러퓨틱스, 인코퍼레이티드	변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
IT1400425B1 (it) *	2010-06-08	2013-05-31	Amsterdam Molecular Therapeutics Bv	Modified snrnas for use in therapy.
TWI541024B (zh)	2010-09-01	2016-07-11	日本新藥股份有限公司	反義核酸
BR112013020273A2 (pt) *	2011-02-08	2016-10-18	Charlotte Mecklenburg Hospital	oligonucleotídeos antissenso
AU2011367230B2 (en)	2011-05-05	2017-08-10	Sarepta Therapeutics, Inc.	Peptide oligonucleotide conjugates
CN108588073A (zh) *	2011-12-28	2018-09-28	日本新药株式会社	反义核酸
BR112016020618B1 (pt) *	2014-03-12	2023-04-04	Nippon Shinyaku Co., Ltd.	Oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido

2015
- 2015-03-11 BR BR112016020618-5A patent/BR112016020618B1/pt active IP Right Grant
- 2015-03-11 SG SG11201607095RA patent/SG11201607095RA/en unknown
- 2015-03-11 HR HRP20190235TT patent/HRP20190235T1/hr unknown
- 2015-03-11 CN CN201911163414.5A patent/CN110951732A/zh active Pending
- 2015-03-11 EP EP15761392.8A patent/EP3118311B1/en active Active
- 2015-03-11 TW TW104107708A patent/TWI672314B/zh active
- 2015-03-11 RS RS20190188A patent/RS58573B1/sr unknown
- 2015-03-11 SM SM20190169T patent/SMT201900169T1/it unknown
- 2015-03-11 UA UAA201610167A patent/UA120849C2/uk unknown
- 2015-03-11 AU AU2015227733A patent/AU2015227733B2/en active Active
- 2015-03-11 TR TR2019/01939T patent/TR201901939T4/tr unknown
- 2015-03-11 RU RU2019130513A patent/RU2730681C2/ru active
- 2015-03-11 NZ NZ724836A patent/NZ724836A/en unknown
- 2015-03-11 CN CN201580012727.4A patent/CN106459955B/zh active Active
- 2015-03-11 CA CA2939948A patent/CA2939948A1/en active Pending
- 2015-03-11 LT LTEP15761392.8T patent/LT3118311T/lt unknown
- 2015-03-11 TW TW108129128A patent/TW201945383A/zh unknown
- 2015-03-11 JP JP2016507800A patent/JP6606488B2/ja active Active
- 2015-03-11 PT PT15761392T patent/PT3118311T/pt unknown
- 2015-03-11 WO PCT/JP2015/057180 patent/WO2015137409A1/ja not_active Ceased
- 2015-03-11 US US15/122,435 patent/US9988629B2/en active Active
- 2015-03-11 SI SI201530597T patent/SI3118311T1/sl unknown
- 2015-03-11 MX MX2016011538A patent/MX2016011538A/es active IP Right Grant
- 2015-03-11 HU HUE15761392A patent/HUE042283T2/hu unknown
- 2015-03-11 KR KR1020167027723A patent/KR102335801B1/ko active Active
- 2015-03-11 EP EP18205909.7A patent/EP3514234A1/en active Pending
- 2015-03-11 PL PL15761392T patent/PL3118311T3/pl unknown
- 2015-03-11 MY MYPI2016703281A patent/MY193708A/en unknown
- 2015-03-11 DK DK15761392.8T patent/DK3118311T3/en active
- 2015-03-11 ES ES15761392T patent/ES2710802T3/es active Active
- 2015-03-11 RU RU2016139108A patent/RU2702424C2/ru active
2016
- 2016-08-23 ZA ZA2016/05864A patent/ZA201605864B/en unknown
- 2016-09-06 IL IL247663A patent/IL247663B/en active IP Right Grant
- 2016-09-07 PH PH12016501761A patent/PH12016501761B1/en unknown
2018
- 2018-02-22 US US15/902,231 patent/US20180179538A1/en not_active Abandoned
2019
- 2019-02-12 CY CY20191100184T patent/CY1121322T1/el unknown
- 2019-06-11 US US16/437,130 patent/US11053497B2/en active Active
2020
- 2020-01-30 AU AU2020200679A patent/AU2020200679B2/en active Active
2021
- 2021-06-30 US US17/364,618 patent/US20220162604A1/en not_active Abandoned
2024
- 2024-11-19 US US18/951,766 patent/US20250145997A1/en active Pending

Also Published As

Publication number	Publication date
US20200149040A1 (en)	2020-05-14
TR201901939T4 (tr)	2019-03-21
KR20160132056A (ko)	2016-11-16
AU2020200679B2 (en)	2022-03-10
ES2710802T3 (es)	2019-04-26
JP6606488B2 (ja)	2019-11-13
HRP20190235T1 (hr)	2019-05-03
TW201945383A (zh)	2019-12-01
CY1121322T1 (el)	2020-05-29
CN106459955A (zh)	2017-02-22
LT3118311T (lt)	2019-04-10
SMT201900169T1 (it)	2019-05-10
PT3118311T (pt)	2019-02-15
WO2015137409A1 (ja)	2015-09-17
EP3118311B1 (en)	2018-12-26
KR102335801B1 (ko)	2021-12-03
JPWO2015137409A1 (ja)	2017-04-06
PH12016501761A1 (en)	2016-11-07
UA120849C2 (uk)	2020-02-25
US20180179538A1 (en)	2018-06-28
AU2015227733A1 (en)	2016-10-20
DK3118311T3 (en)	2019-03-11
IL247663A0 (en)	2016-11-30
BR112016020618A8 (pt)	2021-07-13
RU2016139108A3 (pl)	2018-08-06
SG11201607095RA (en)	2016-10-28
NZ724836A (en)	2022-07-01
CN110951732A (zh)	2020-04-03
TWI672314B (zh)	2019-09-21
RU2730681C2 (ru)	2020-08-24
RU2019130513A3 (pl)	2020-03-13
BR112016020618A2 (pt)	2017-08-15
CA2939948A1 (en)	2015-09-17
ZA201605864B (en)	2018-12-19
US20220162604A1 (en)	2022-05-26
MX2016011538A (es)	2017-04-13
US9988629B2 (en)	2018-06-05
RU2702424C2 (ru)	2019-10-08
TW201540724A (zh)	2015-11-01
HUE042283T2 (hu)	2019-06-28
CN106459955B (zh)	2019-12-20
SI3118311T1 (sl)	2019-05-31
EP3118311A1 (en)	2017-01-18
EP3514234A1 (en)	2019-07-24
BR112016020618B1 (pt)	2023-04-04
RU2016139108A (ru)	2018-04-13
US11053497B2 (en)	2021-07-06
PH12016501761B1 (en)	2016-11-07
AU2015227733B2 (en)	2019-10-31
RU2019130513A (ru)	2019-10-10
AU2020200679A1 (en)	2020-02-20
US20170067048A1 (en)	2017-03-09
US20250145997A1 (en)	2025-05-08
RS58573B1 (sr)	2019-05-31
EP3118311A4 (en)	2017-10-11
MY193708A (en)	2022-10-26
IL247663B (en)	2020-06-30

Publication	Publication Date	Title
DK3981437T3 (da)	2025-01-13	Nukleinsyrevacciner
HRP20190235T1 (hr)	2019-05-03	Antisensna nukleinska kiselina
HUE049405T2 (hu)	2020-09-28	Nukleáz-közvetített DNS-összeállítás
DK3183051T3 (da)	2020-06-02	Væske-til-luftmembranenergivekslere
DK3134402T3 (da)	2020-07-20	4-amino-imidazoquinolinforbindelser
DK3211743T3 (da)	2019-12-16	Ø-til-netværk-omskiftningsfremgangsmåde
DK3006072T3 (da)	2021-10-25	Karadgang
DK3222714T3 (da)	2019-12-09	Phytasemutanter
DK3119396T3 (da)	2021-05-31	Muscarinreceptoragonister
EP3286549A4 (en)	2019-04-17	BIOSENSOR
DK3094731T3 (da)	2019-08-05	Saccharidmodificerede nukleinsyremolekyler
EP3230438C0 (en)	2024-12-04	N-GLYCOSYLATION
EP3156789C0 (en)	2024-01-03	BIOSENSOR
DK3310450T3 (da)	2019-08-05	Olie-vand-separator
EP4011484C0 (en)	2025-09-24	CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK4242916T3 (da)	2025-12-15	Forstøver
DK3183340T3 (da)	2019-08-19	Termolabile exonukleaser
DE112015001664A5 (de)	2016-12-29	Betätigungsaktuator
DK3154703T3 (da)	2020-11-16	Fuldkappe-snekkecentrifuge
EP3387414A4 (en)	2019-07-10	BIOSENSOR
EP3371575A4 (en)	2019-06-26	BIOSENSOR
DE112015005041A5 (de)	2017-08-31	Gargerätevorrichtung
IL249254A0 (en)	2017-02-28	Gene expression system
DK3110439T3 (da)	2019-05-13	Pcsk9-vacciner
DE102014000623A8 (de)	2016-10-13	Halbhohlnietelement